All sponsors

Biogen $BIIB

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS23
PHASE 3 / 2-317
RECRUITING8
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO40%

Delay Index: of 15 active trials registered more than a year ago, 6 have moved their primary completion (readout) date by more than 6 months since first registration (median +3.3 months). See all sponsors →

Open Biogen on the live radar map → 📅 $BIIB readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
CELIA
NCT05399888
P2Active, not recruitingMild Cognitive Impairment Due to Alzheimer's Disease; Alzheimer's Disease Dementia4162026-03-11 (-9 mo)
TOPAZ-2
NCT04961567
P3Active, not recruitingLupus Erythematosus, Systemic5622026-09-27 (+15 mo)
TOPAZ-1
NCT04895241
P3Active, not recruitingLupus Erythematosus, Systemic5482026-09-30 (+18 mo)
AMETHYST
NCT05531565
P2/3Active, not recruitingSubacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus4502026-10-20 (+3 mo)
TRANSCEND
NCT06685757
P3Active, not recruitingAntibody-mediated Rejection1322026-12-01
BIIB017 (peginterferon beta-1a)
NCT03958877
P3Active, not recruitingMultiple Sclerosis, Relapsing-Remitting1522027-05-20 (+50 mo)
PREVAIL
NCT06935357
P3RecruitingImmunoglobulin A Nephropathy (IgAN)4542027-05-31
ATLAS
NCT04856982
P3Active, not recruitingAmyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation1582027-08-07 (+12 mo)
ASCEND
NCT05067790
P3Active, not recruitingSpinal Muscular Atrophy452027-09-24 (+3 mo)
BRAVE
NCT06953583
P3Active, not recruitingFriedreich Ataxia2552027-11-16
GRAVITATE
NCT07722546
P2RecruitingGraves' Disease602028-01-31
TRANSPIRE
NCT07219043
P2RecruitingMicrovascular Inflammation812028-02-10
SOLAR
NCT07444476
P3RecruitingSpinal Muscular Atrophy902028-06-23
Felzartamab
NCT07889362
P2Not yet recruitingImmunoglobulin A Nephropathy252028-08-13
MYAMERGE
NCT07939802
P2Not yet recruitingGeneralized Myasthenia Gravis752028-09-19
STELLAR-1
NCT07221669
P3RecruitingMuscular Atrophy, Spinal302028-11-28
AMETHYST LTE
NCT06044337
P3Enrolling by invitationSubacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus3062029-06-26
STELLAR-2
NCT07444450
P3RecruitingMuscular Atrophy, Spinal422029-07-27
PROMINENT
NCT06962800
P3RecruitingPrimary Membranous Nephropathy1802030-01-28 (+13 mo)
Felzartamab
NCT07444489
P3Enrolling by invitationAntibody-mediated Rejection; Microvascular Inflammation2012031-12-31
EMERALD
NCT05352919
P3Enrolling by invitationSystemic Lupus Erythematosus (SLE)8642032-05-03 (+43 mo)
HORIZON
NCT07855211
P1/2RecruitingAmyotrophic Lateral Sclerosis692034-01-23
VOYAGE
NCT07483632
P3Not yet recruitingRelapsing Forms of Multiple Sclerosis1852034-07-28